Dysregulation of apoptosis in hepatocellular carcinoma cells

Isabel Fabregat

Isabel Fabregat, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) and Universitat de Barcelona, 08907 L’Hospitalet, Barcelona, Spain
Author contributions: The author collected all the scientific information, wrote the paper and designed the figures.
Correspondence to: Dr. Isabel Fabregat, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Laboratori d’Oncologia Molecular, Hospital Duran i Reynals, Gran Via, Km 2,7. L’Hospitalat, 08907 Barcelona, Spain. ifabregat@idibell.org
Telephone: +34-932-607828 Fax: +34-932-607426
Received: November 14, 2008 Revised: December 10, 2008
Accepted: December 17, 2008
Published online: February 7, 2009

Key words: Hepatocellular carcinoma cells; Apoptosis; Liver cancer; p53, Transforming growth factor-beta; Liver inflammation; Epithelial-to-mesenchymal transition

Peer reviewer: Henning Schulze-Bergkamen, MD, Henning Schulze-Bergkamen, First Medical Department, University of Mainz, Langenbeckstr. 1, 55101 Mainz, Germany


INTRODUCTION

Apoptosis represents a physiological way to eliminate excess cells during both liver development and regeneration[1]. Indeed, insufficient apoptosis has been associated with development and progression of tumors of the liver and the biliary tree[1,2]. Hepatocellular carcinoma (HCC) is a major health problem, being the sixth most common cancer world-wide[3]. It is a heterogeneous tumor commonly associated with chronic liver diseases which frequently culminate in cirrhosis, such as alcoholic cirrhosis and chronic hepatitis B and C infections. During recent years, major advancements in the knowledge of this complex disease have been reported[4]. This review is an effort to update the recent relevant contributions reporting molecular alterations for HCC that induce an imbalance in the regulation of apoptosis.

THE P53 PATHWAY

Among the most common alterations observed in HCC are mutations in the p53 tumor suppressor gene (TP53)[5]. Different chemotherapeutic agents require p53 to induce apoptosis. Indeed, tumors with a disruption in the p53 pathway are generally resistant to chemotherapy. The presence of specific mutational hotspots in TP53 in different types of human cancer implicates environmental carcinogens and endogenous processes. In this sense, somatic mutations at the third base in codon 249 of TP53 in HCC have been related to exposure to aflatoxin B1 (AFB1), in association with HBV infection[6]. Chronic infection with HBV and HCV viruses and exposure to oxidative stress, including hemochromatosis or inflammation, induce damage in the DNA and mutations in cancer-related genes, including TP53. Thus, it would
seem plausible that p53 mutation might operate in either HCC initiation or progression, depending on the context. However, adenoviral delivery of p53 recombinant DNA into mice models bearing hepatocellular carcinomas did not apparently suppress tumor growth[18]. De-Pinho et al in a recent work[19] have helped to clarify this point. They have demonstrated that the effect of p53 loss in hepatocellular carcinoma that is associated with chronic liver disease is dependent on cellular context, in particular intact or dysfunctional telomeres, and they have hypothesized that a decreased p53 function might contribute to hepatocyte survival in the presence of telomere-induced chromosomal instability.

THE TGF-β PATHWAY

The transforming growth factor-beta (TGF-β) family of cytokines plays a physiological role during embryonic development and its misregulation can result in tumorsgenesis[7]. TGF-β-1 is an important regulatory suppressor factor in hepatocytes, inhibiting proliferation[5] and inducing cell death[9]. Paradoxically, TGF-β may also modulate other pro-tumorigenic processes, such as cell invasion, immune regulation or microenvironment modification[7]. Blocking TGF-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells[10]. Furthermore, liver tumors expressing late TGF-β-responsive genes (anti-apoptotic and metastatic) display a higher invasive phenotype and increased tumor recurrence when compared to those that show an early TGF-β signature (suppressor genes)[11]. Indeed, the escape from the antiproliferative and pro-apoptotic actions of TGF-β might be a prerequisite for hepatocarcinoma progression[12].

Disruption of the TGF-β pathway occurs in HCC[13,14] and might cause dysregulation of apoptosis. In favour of this hypothesis, recent studies have demonstrated that overexpression of SMAD3 reduces susceptibility to develop hepatocarcinoma, by sensitizing hepatocytes to apoptosis through down-regulation of Bel-2[15,16]. However, perturbations at receptor or SMAD levels do not appear to be as frequent as they are in colon or pancreatic cancer[17] and expression of TGF-β is up-regulated in a great percentage of HCC patients[18-20]. Thus, other possible ways to disrupt TGF-β signalling might exist and they remain to be explored. Interestingly, Mishra et al have recently demonstrated that HCC might arise from loss of TGF-β signalling adaptor protein embryonic liver foldrin (ELF), a crucial Smad3/4 adaptor[21,22]. HCC cells might also overexpress a specific set of microRNAs (miRNAs) that would allow the escape from TGF-β-induced apoptosis[23]. However, recent results have indicated that TGF-β might play a dual role in controlling apoptosis in hepatocytes and hepatoma cells. On one hand, it induces cell death, but on the other it could activate anti-apoptotic signals, the epidermal growth factor receptor (EGFR) being required for this effect[18-20]. Indeed, EGFR is an important survival signal for TGF-β-induced apoptosis in hepatocytes[21]. The enzyme phosphatidylinositol 3-kinase (PI3K) mediates the effect of EGF on TGF-β-induced death by acting upstream from the mitochondrial changes, probably counteracting TGF-β-induced oxidative stress[22]. The autocrine loop of EGFR activated by TGF-β in hepatoma cells would require a high activity of TACE/ADAM17[23], the metalloprotease responsible for shedding of the pro-tumor necrosis factor (proTNF-α) that it is also necessary for shedding of the EGF family of growth factors[24]. Although the possible role of an increased expression of TACE/ADAM17 in the development of human hepatocellular carcinoma (HCC) has been barely studied, a recent report indicates that the quantities of ADAM17 mRNA vary among different pathological types of HCC, but are significantly higher in poorly differentiated HCC than in well or moderately differentiated HCC[24]. Overexpression of TACE/ADAM17 might confer an advantage on HCC cells by impairing TGF-β-induced apoptosis through transactivation of the EGFR. Concluding, HCC cells might impair the suppressor arm in TGF-β-signalling, with enhancement of the response to this factor in terms of tumor progression and invasion (Figure 1).

THE DEATH RECEPTOR PATHWAYS

HCCs show resistance to apoptosis mediated by several death receptors. The majority of the HCCs show one or more alterations in the Fas pathway molecules, which inhibit Fas-mediated apoptosis[25]. The status of Fas and Fas ligand (FasL) expression can predict HCC recurrence[26]. Loss of response to Fas in HCC cells may be produced either by down-regulation of Fas expression[27-29], concomitant with decreased expression of downstream molecules, such as FADD or FLICE[30], or by up-regulation or over-activation of molecules that counteract its pro-apoptotic effect, including nuclear factor-kappaB (NF-κB), Bel-2 or Bcl-XL[31-33]. The cellular FLICE/caspase-8-inhibitory protein (cFLIP), an intracellular inhibitor of caspase-8 activation, is constitutively expressed in human HCC cell lines and displays higher levels in HCC tissues than in nontumor liver tissues[31]. It has also been described that HCC tissues show overexpression of BRE, an antiapoptotic protein that binds to the cytoplasmic domains of tumour necrosis factor (TNF) receptor-1 and Fas, attenuating death-receptor initiated apoptosis[34]. Furthermore, it has been suggested that extracellular factors might counteract Fas-induced apoptosis in HCC cells. Indeed, hepatocyte growth factor (HGF), through activation of the PI3K/ AKT pathway, suppresses Fas-mediated cell death in human hepatoma cell lines, by inhibiting Fas-death-inducing signalling complex (DISC) formation, especially FADD and caspase 8 interaction[16] (Figure 2).

TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in various transformed cell lines but not in almost normal tissues[35]. HCC cells constitutively express TRAIL mRNA and protein, but there are contradictory and confusing data about the expression of the different TRAIL receptors in HCC cells and tissues[35-37]. Certain evidence indicates that most HCC cells are insensitive towards TRAIL-mediated apoptosis, suggesting that the presence of mediators can inhibit the
TRAIL cell-death-inducing pathway in HCC\(^{[36,37]}\). It has been reported that hepatitis B virus core protein inhibits TRAIL-induced apoptosis by blocking the expression of the TRAIL receptor 2 (TRAIL-R2/DR5)\(^{[38]}\). Overactivation of NF-kB and Bcl-X\(_i\) in HCC cells might also restrain the TRAIL-mediated apoptosis\(^{[39]}\). After an initial debate about the potential liver toxicity of TRAIL in freshly isolated human hepatocytes\(^{[37]}\), there is a recent interest in the development of new therapeutic approaches that can sensitize HCC cells to TRAIL-induced apoptosis. Indeed, it has been proposed that TRAIL, in combination with chemotherapeutic agents, may have potential in the treatment of HCC\(^{[38]}\). Of clinical relevance, proteasome inhibitors and histone deacetylase (HDAC) inhibitors might sensitize HCC cells but not primary human hepatocytes for TRAIL-induced apoptosis\(^{[41,62]}\).

**ALTERATIONS IN THE EXPRESSION OR FUNCTION OF APOPTOSIS REGULATORY PROTEINS**

It is worthy of note that many of the genetic alterations observed in HCC lead to an imbalance in the pro- and anti-apoptotic members of the Bcl-2 family\(^{[40]}\). Bcl-X\(_i\) is overexpressed in a great percentage of HCCs\(^{[44]}\), and so is Mcl-1\(^{[43]}\). In contrast, pro-apoptotic members of the family, such as Bax or Bcl-X\(_l\) are down-regulated in HCC with dysfunction in the p53 pathway\(^{[46]}\). Furthermore, recent results have indicated that some pro-apoptotic members of the BH-3-only family, such as Bid, show decreased expression in HCC related to hepatitis B or C infection\(^{[47]}\).

Recent investigations have revealed that nearly 90% of clinical tumors from advanced HCC patients express high levels of X-linked inhibitor-of-apoptosis protein (XIAP), a well known inhibitor of caspases. Studies in established HCC cell lines with different metastatic capabilities indicated a correlation of metastasis with resistance to apoptosis and increased expression of XIAP\(^{[48]}\). Interestingly, it had previously been suggested that XIAP might also function as a cofactor in TGF-\(\beta\) signalling\(^{[49]}\). Thus, overexpression of XIAP might confer resistance to the apoptotic effects of TGF-\(\beta\), allowing HCC cells to respond to this cytokine in terms of migration and invasion. Genome-wide analyses of tumors in a mouse model of liver cancer and in HCC tissue have recently revealed a recurrent amplification in a region of human chromosome 11q22, delineating a recurrent amplification in the amplicon\(^{[50]}\). The p53 function of apoptosis regulatory proteins is also overexpressed in a great percentage of HCCs\(^{[36,63]}\) that protect themselves from death stimuli\(^{[61]}\), and it accounts in a large part for the desensitization of liver tumor cells to TRAIL and CD95. Interestingly, blockade of EGF or c-Src in primary hepatocytes only marginally increases cell death\(^{[16,60]}\), which indicates that both tyrosine kinases are critical effectors that specifically protect liver cancer cells from death stimuli, providing a weak point in cancer cells for a potential therapeutic approach.

Signal transducer and activator of transcription (STAT) proteins become activated by tyrosine kinases in response to cytokines and growth factors. It has been reported that suppressor of cytokine signalling (SOCS)-1 and (SOCS)-3, negative regulators of the JAK2-STAT signalling pathway, are silenced by methylation in human hepatoma cell lines and HCC tissues, which leads to constitutive activation of STAT3 in these cells\(^{[82,63]}\). Deletion of the (SOCS)-3 gene in hepatocytes promotes the activation of STAT3, resistance to apoptosis and accelerated proliferation, resulting in enhanced hepatocarcinogenesis\(^{[24]}\). In addition, hepatitis C virus (HCV) core protein exerts an inhibitory effect on (SOCS)-1 gene expression\(^{[44]}\). Hepatitis viruses also activate STAT-3 via oxidative stress\(^{[66,68]}\), which might contribute to cellular transformation\(^{[44]}\). Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to apoptosis induced by TRAIL or drugs\(^{[77]}\).

The PI3K/Akt pathway is also altered in HCC. The expression of the PTEN gene product is reduced or absent in almost half of HCCs and hepatocyte-specific abrogation of PTEN expression in mice results in the development of HCCs\(^{[73]}\). Recent results have indicated that the expression of a negative regulator of PI3K (phosphatidylinositol-3-kinase interacting protein I: PIK3IP1) is reduced in most cases of human HCC, pointing to a tumor suppressor-like function for this protein\(^{[73]}\). Interestingly, hepatic overexpression of PIK3IP1 negatively regulates PI3K activity in the tissue and suppresses the development of HCC\(^{[73]}\).

Overexpression of Ras proteins is frequently observed in HCC\(^{[64]}\), at least in part due to epigenetic silencing of inhibitors of the Ras pathway\(^{[73]}\). Furthermore, it has been reported that the expression of different ERK inhibitors, such as the Spred family of Ras/ERK inhibitors or the dual-specificity phosphatase-1 (DUSP1), is dysregulated in the expression of pro- and anti-apoptotic proteins, which favours cell survival (Figure 2).

**OVERACTIVATION OF SURVIVAL SIGNALS IN HCC CELLS**

Some autocrine signal activators, such as EGF receptor (EGFR) ligands, might protect liver tumor cells from apoptosis induced by stress, physiological factors or pro-apoptotic drugs\(^{[56]}\). Dysregulation of growth factor signalling, including EGF and IGF-1 pathways, has been well established in human HCCs\(^{[37,58]}\). Viral hepatitis infections might contribute to the enhancement of the expression of EGFR ligands\(^{[49]}\). The tyrosine kinase p60\(_{v-	ext{src}}\) is also overactivated in hepatoma cells\(^{[56,68]}\) that protect themselves from death stimuli\(^{[61]}\), and it accounts in a large part for the desensitization of liver tumor cells to TRAIL and CD95. Interestingly, blockade of EGFR or c-Src in primary hepatocytes only marginally increases cell death\(^{[16,60]}\), which indicates that both tyrosine kinases are critical effectors that specifically protect liver cancer cells from death stimuli, providing a weak point in cancer cells for a potential therapeutic approach.
HCC is known to be associated with inflammation. Activated R-ASV oncogene collaborates with the hepatitis B virus HBx protein to transform cells by suppressing HBx-mediated apoptosis. Thus, dysregulation of the Ras pathway might also be playing a role in balancing pre-neoplastic hepatocytes towards survival in HBV- or HCV-mediated HCC.

In summary, different molecular alterations may contribute to an enhancement of anti-apoptotic signals in HCC cells that allow them to survive pro-apoptotic stimuli (Figure 3).

LIVER INFLAMMATION AND RESISTANCE TO APOPTOSIS

A link between inflammation and liver cancer was suspected some years ago, but the precise mechanisms are just beginning to be understood. Recent experimental data support the hypothesis that inflammation promotes carcinogenesis and that NF-κB signalling is at the heart of such inflammation. Different studies have implicated members of the NF-κB/Rel family in both HBV- and HCV-induced neoplastic development of the liver.

Several mechanisms have been proposed for activation of NF-κB by the hepatitis virus. Overall, inflammatory hepatitis might activate NF-κB by the concerted action of cytokines, such as TNF-α, chemokines or interleukins, and viral proteins, which likely will promote cell survival of pre-cancerous hepatocytes. Furthermore, a correlation between EGFR ligands and NF-κB activity has been provided by studies in transforming growth factor-alpha (TGF-α)/c-Myc mice. Indeed, an important role for NF-κB in inhibiting c-Myc-induced apoptosis was found essential for hepatocarcinogenesis. Two pro-survival NF-κB targets are an antia apoptotic member of the Bcl-2 family, Bel-2, and a member of the caspase inhibitors, XIAP, which are frequently overexpressed in human HCCs, as commented above. Interestingly, the NF-κB/Bel-2/XIAP axis potently counteracts the TGF-β-induced apoptosis and exerts a general cytoprotective role on preneoplastic hepatocytes. Recent results also link NF-κB to the increase in the autocrine expression of EGF receptor ligands, such as TGF-α, in hepatocytes and hepatoma cells. In summary, overactivation of the NF-κB pathway might generate resistance to apoptosis, through different mechanisms, in HCC cells (Figure 2).

Many epidemiological studies demonstrate that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) reduces the incidence and mortality of certain malignancies, especially gastrointestinal cancer. The cyclooxygenase (COX) enzymes are well known targets of NSAIDs. Overexpression of COX-2 in HCC cells increases proliferation and survival through Akt activation. Accordingly, recent evidence indicates that selective inhibition of COX-2 in HCC cells leads to a marked induction of apoptosis and inhibition of proliferation and, thus, may offer therapeutic and preventive poten-
tial in human hepatocarcinogenesis\[80\]. COX-2 inhibitors might induce apoptosis signalling in HCC cells via death receptors and mitochondria\[89,90\]. Recent data have demonstrated that simultaneous inhibition of PI3K/Akt/mTOR and COX-2 activity in in vitro models causes massive apoptosis of neoplastic hepatocytes\[90\].

EPITHELIAL-MESENCHYmal TRANSITIONS AND APOPTOSIS RESISTANCE

During later stages in the development of liver tumors, a loss in cell-cell contacts and the acquisition of fibroblast-like phenotype is observed. This phenomenon, known as epithelial-to-mesenchymal transition (EMT), might contribute to increasing the migratory and metastatic capabilities of the cells\[50\]. Cytokines, such as TGF-β and extracellular matrix molecules are thought to fundamentally contribute to the microenvironmental interaction between stromal and malignant cells, and provide the basis for a broad repertoire of epithelial transdifferentiation. Interestingly, EMT of liver cells also results in enhanced survival due to overactivation of anti-apoptotic signals\[3] (Figure 1).

A high percentage of human HCCs show high levels of β-catenin\[5,95\], either through stabilizing mutations of the β-catenin or overexpression of FZD, therefore favouring the intracellular accumulation of the protein\[95\]. Furthermore, certain evidence indicates that TGF-β might induce nuclear β-catenin accumulation, through induction of PDGF signalling\[97\] (Figure 1). β-catenin expression leads to elevated EGFR levels in hepatocytes and immunohistological analysis shows high correlation between the expression of nuclear/cytoplasmic β-catenin and EGFR in most hepatoblastomas\[5\]. β-catenin also participates in homotypic cell-cell interactions through its association with E-cadherin. Thus, β-catenin accumulation in HCC cells might contribute to impairing E-cadherin expression, mediating the EMT process, migration and survival. Indeed, there is evidence suggesting that up-regulation of CTNNBI, the gene encoding for β-catenin, also contributes to the enhancement of hepatocellular carcinoma cell survival\[98\].

In summary, a significant number of relevant molecular mechanisms altered in HCC initiation and progression are compromising the balance between survival and apoptotic signals in the pre-neoplastic hepatocytes. Some physiological pro-apoptotic molecules are down-regulated or inactivated in HCC, but the balance between death and survival is mainly disrupted due to overactivation of anti-apoptotic signals. Therefore, liver cancer cells might show stronger requirements of these intracellular pathways to survive. The absence of standard systemic therapy for advanced cases of HCC has changed with the recent positive randomized trial testing the multikinase sorafenib, which represents a breakthrough in the management of this neoplasm\[55,58\]. Interestingly, sorafenib induces tumor cell apoptosis in HCC cells, through, at least, inhibiting the RAF/MEK/ERK pathway\[99\]. Similar situations might be found with other multikinase inhibitor drugs that are on the way towards approval for HCC therapy\[88,90,98\].

Of relevance here is certain evidence indicating that erlotinib-induced growth inhibition in HCC cells correlates with overexpression of pro-apoptotic factors like caspase and gadd, as well as down-regulation of anti-apoptotic factors, such as Bel-2.\[101\]. Another receptor tyrosine kinase inhibitor, sunitinib, which has also shown intriguing outcomes in advanced HCC\[102\], is a strong apoptosis inducer in different tumor cells, an effect that is enhanced in the presence of inhibitors of the PI3-K/Akt/mTOR pathway\[103\]. Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, has been proven to be efficient in inhibiting the growth of nonmetastatic HCC\[104\]. Interestingly, recent evidence indicates that VEGF signalling inhibitors might be effective in inhibiting tumorigenesis more through their pro-apoptotic than their anti-angiogenic properties\[105\]. Therefore, therapeutic strategies to selectively inhibit anti-apoptotic signals in HCC cells might have the potential to provide powerful tools in the future to treat liver cancer.

ACKNOWLEDGMENTS

Author acknowledges the help of Javier Marquez in the editing of this manuscript.

REFERENCES

8 Carr BL, Hayashi I, Branum EL, Moses HL. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res 1986; 46: 2330-2334
11 Coulouarn C, Factor VM, Thorgerisson SS. Transforming
growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. **Hepatology** 2008; 47: 2059-2067

12 **Yang Y**, Zhang GM, Feijenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. **Cancer Cell** 2006; 9: 445-457


17 **Petrocco F**, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. **Cancer Res** 2008; 68: 8191-8194


23 **Borrell-Pages M**, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF- 


36 **Chen XP**, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing ligand and Fas and Fas ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. **World J Gastroenterol** 2003; 9: 2433-2440

37 **Herr I**, Schemper M, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. **Hepatology** 2007; 46: 266-274


of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. *Hepatology* 2006; 43: 425-434


70 *Choudhari SR*, Khan MA, Harris G, Picker D, Jacob GS, Block T, Shalitubhai K. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular cancer cells to an anticancer agent, Aliprimod. *Mol Cancer Ther* 2007; 6: 112-121


74 *Calvisi DF*, Ladu S, Gorden A, Fabina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. *Gastroenterology*


Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-1915

Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298-1305


S-Editor Tian L  L-Editor Logan S  E-Editor Ma WH

ISSN 1007-9327  CN 14-1219/R  World J Gastroenterol  February 7, 2009  Volume 15  Number 5